They show that widespread treatment has led to a stark reduction in the population prevalence of resistant HIV, highlighting the critical role in universal access to treatment in improving individual and population health and continuing progress to end the AIDS pandemic.

Panelists shared how their organizations have tackled stigma and reflected on recent successes in addressing the HIV epidemic in Baltimore and beyond, including the recent legislative win in Maryland to modernize HIV laws.

Both regimens of HepB-CpG vaccine achieved a superior seroprotection response compared with 3 doses of HepB-alum vaccine, potentially offering PWH better protection against HBV infection

In a phase 3 clinical trial, PWH with nonresponse to prior hepatitis B vaccination were randomly assigned to receive 2 doses of HepB-CpG vaccine or 3 doses of HepB-alum vaccine of HepB-alum vaccine.

Nonresponse to hepatitis B vaccine is common among people with HIV (PWH), resulting in hepatitis B virus (HBV) vulnerability.